Side Effects of NOT Taking Eplerenone
If you have heart failure with reduced ejection fraction after a heart attack or primary aldosteronism requiring medical treatment, not taking eplerenone (or an equivalent mineralocorticoid receptor antagonist) means you are forgoing a proven 15% reduction in mortality and significant protection against cardiovascular hospitalization. 1, 2
Mortality and Morbidity Consequences
Heart Failure Post-Myocardial Infarction
- Increased death risk: The EPHESUS trial demonstrated a 15% relative risk reduction in all-cause mortality with eplerenone in post-MI patients with left ventricular ejection fraction ≤40% and heart failure. 1, 2
- Higher hospitalization rates: Without eplerenone, patients face a 35% higher relative risk of hospitalization for worsening heart failure. 1
- Missed additive benefits: These mortality and morbidity benefits are additive to those provided by ACE inhibitors and β-blockers, meaning you lose this additional layer of protection. 2
Primary Aldosteronism
- Uncontrolled hypertension: Without mineralocorticoid receptor antagonist therapy, blood pressure remains poorly controlled, with systolic BP reductions of 40-60 mmHg being missed. 3
- Persistent hypokalemia: Potassium levels remain dangerously low without treatment, increasing arrhythmia risk. 3, 4
- Progressive target organ damage: Untreated primary aldosteronism leads to:
Quality of Life Impact
Functional Status
- Worse NYHA functional class: Patients not receiving aldosterone antagonist therapy maintain worse heart failure symptoms and functional limitations. 1
- Reduced exercise capacity: Without treatment, cardiac performance remains impaired with lower ejection fraction and cardiac output. 5
Symptom Burden
- Persistent fluid retention: Without the natriuretic effects of mineralocorticoid receptor blockade, volume overload and edema persist. 3
- Ongoing fatigue: Untreated heart failure symptoms including fatigue and dyspnea continue to limit daily activities. 6
Long-Term Cardiovascular Consequences
Cardiac Remodeling
- Continued adverse remodeling: Eplerenone attenuates myocardial remodeling post-MI; without it, pathological remodeling progresses unchecked. 7
- Progressive left ventricular dysfunction: Cardiac function continues to deteriorate without the cardioprotective effects of aldosterone blockade. 4, 5
Renal Deterioration
- Accelerated kidney disease: In primary aldosteronism, untreated patients experience progressive glomerular hypertrophy, tubular injury, and declining glomerular filtration rate. 4, 5
- Increased proteinuria: Urinary albumin excretion worsens without mineralocorticoid receptor antagonism. 4
Risk Stratification for Untreated Disease
Highest Risk Populations (Greatest Harm from Non-Treatment)
- Post-MI with LVEF ≤35% and heart failure symptoms: This population has the strongest mortality benefit data, with number needed to treat of 9 to prevent one death over 2 years. 1
- Primary aldosteronism with both diabetes and CKD: These patients face 2.5-fold higher cardiovascular death/hospitalization risk when untreated. 8
- Severe heart failure (NYHA class III-IV): Absolute risk reduction in mortality is 11.4% over 2 years without treatment. 1
Moderate Risk (Significant Benefit Foregone)
- Chronic systolic heart failure with mild symptoms (NYHA class II): The EMPHASIS-HF trial showed significant reductions in CV mortality and HF hospitalization even in this milder population. 6
- Resistant hypertension from primary aldosteronism: Blood pressure remains uncontrolled despite multiple agents, increasing stroke and MI risk. 3, 9
Important Clinical Context
The decision not to use eplerenone should only occur when absolute contraindications exist: serum potassium >5.5 mEq/L, creatinine clearance ≤30 mL/min, or concurrent use of strong CYP3A inhibitors. 10
Common pitfall: Clinicians often withhold aldosterone antagonists due to fear of hyperkalemia, but this fear must be balanced against the substantial mortality benefit. With proper patient selection (adequate renal function, normal baseline potassium) and monitoring, hyperkalemia risk is manageable. 11, 2, 9
Alternative consideration: If eplerenone is unavailable or cost-prohibitive, spironolactone provides equivalent mortality benefit at lower cost, though with higher rates of gynecomastia (10-52% depending on dose) and sexual side effects. 3, 12, 13